EXPAREL — Class II drug recall D-0621-2020
Terminated recall by Pacira Pharmaceuticals, Inc., reported 2019-12-11, distributed nationwide. Sub Potent Drug: Out of Specification (OOS)
| Recall number | D-0621-2020 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Pacira Pharmaceuticals, Inc., San Diego, CA, United States |
| Recall initiated | 2019-11-21 |
| Classified | 2019-12-10 |
| Reported by FDA | 2019-12-11 |
| Terminated | 2020-06-03 |
| Distributed | Nationwide (US) |
| Quantity | 910 |
| Reason classes | specification failure |
| NDC | 65250-0133, 65250-0133-04, 65250-0133-09, 65250-0133-10, 65250-0266, 65250-0266-04, 65250-0266-09, 65250-0266-20 |
| Lot numbers | 098214, 19-5002 |
| Expiration dates | 2019-12-20 |
Product
EXPAREL, Bupivicaine Liposome Injectable Suspension, 1.3%, 266 mg/20 mL (13 mg/mL), Sterile, 20 mL vial, Rx only, Manufactured by: Pacira Pharmaceuticals, Inc. San Diego, CA 92121. NDC: 65250-266-20,
Reason for recall
Sub Potent Drug: Out of Specification (OOS)
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0621-2020. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.